Magnus Expands Access to 5-Day SAINT® Depression Therapy as Leading Health Systems Scale Nationwide Adoption

Key Takeaways

• SAINT now offered at 14 states via major health systems
• Coverage expands to over 80 million Medicare and commercial lives
• 79% remission achieved in average 2.6 days in trials
• Sustained remission observed for roughly 20 months post‑treatment
• Low NNT of 3.4 underscores high treatment efficiency

Pulse Analysis

Depression remains a public‑health crisis, affecting roughly 48 million Americans and straining traditional pharmacologic and psychotherapy approaches. SAINT® distinguishes itself as the first FDA‑cleared, five‑day accelerated neuromodulation therapy, earning Breakthrough Device status and CMS innovation support. By targeting specific brain circuits with functional MRI guidance, it promises rapid symptom relief, a critical advantage for patients who have exhausted standard treatments.

Magnus Medical’s latest rollout brings SAINT to 14 states through marquee health‑system partners such as Cleveland Clinic, UPMC, and HCA Healthcare. Simultaneously, payer reimbursement now spans more than 80 million covered lives, blending Medicare fee‑for‑service with expanding commercial plans. This dual thrust of provider adoption and insurer backing accelerates patient access, creates new revenue streams for participating hospitals, and positions Magnus as a leading player in the emerging neuro‑modulation market.

Robust clinical evidence underpins the commercial push: 79% of trial participants achieve remission in just 2.6 days, with an average durability of 20 months and a low number‑needed‑to‑treat of 3.4. Such outcomes not only improve patient quality of life but also reduce long‑term healthcare costs associated with chronic depression. Investors are watching closely as Magnus expands its pipeline to other neuropsychiatric disorders, signaling broader growth potential beyond MDD.